NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 11.30 against a street estimate of 11.81 — a miss of 4.3%.
with an average price target of ₹2,085.00.
MIXED Q1 FY27 revenue grew 10.1% YoY to ₹151.8B; margins expanded on product mix despite lenalidomide loss. U.S. generics declined 9.7%; innovative medicines +12.8%. India +16%, semaglutide gaining traction. Organon closing expected Q4 FY27. Q1 FY27 India momentum accelerating; U.S. specialty growth offset by generic erosion; emerging markets and ROW pressured by macro/geopolitical factors. Analysts probed U.S. generic decline, semaglutide supply/competition, and specialty product ramp. Management emphasized launches are early-stage; avoided product-specific targets; cited macro headwinds in emerging markets. 2026-07-31…
Full summary in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Sun Pharmaceutical Industries Limited — free to start.
Google PlayApp StoreData updated 2026-08-05.